Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 248

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study

Open access
Arabi, Yaseen M, Shalhoub, Sarah, Mandourah, Yasser, Al-Hameed, Fahad, Al-Omari, Awad, Al Qasim, Eman, Jose, Jesna, Alraddadi, Basem, Almotairi, Abdullah, Al Khatib, Kasim, Abdulmomen, Ahmed, Qushmaq, Ismael, Sindi, Anees A, Mady, Ahmed, Solaiman, Othman, Al-Raddadi, Rajaa, Maghrabi, Khalid, Ragab, Ahmed, Al Mekhlafi, Ghaleb A, Balkhy, Hanan H, Al Harthy, Abdulrahman, Kharaba, Ayman, Gramish, Jawaher A, Al-Aithan, Abdulsalam M, Al-Dawood, Abdulaziz, Merson, Laura, Hayden, Frederick G, Fowler, Robert·2020·Clinical Infectious Diseases

Abstract

Background: The objective of this study was to evaluate the effect of ribavirin and recombinant interferon (RBV/rIFN) therapy on the outcomes of critically ill patients with Middle East respiratory syndrome (MERS), accounting for time-varying confounders. Methods: This is a retrospective cohort study of critically ill patients with laboratory-confirmed MERS from 14 hospitals in Saudi Arabia diagnosed between September 2012 and January 2018. We evaluated the association of RBV/rIFN with 90-day mortality and MERS coronavirus (MERS-CoV) RNA clearance using marginal structural modeling to account for baseline and time-varying confounders. Results: Of 349 MERS patients, 144 (41.3%) patients received RBV/rIFN (RBV and/or rIFN-α2a, rIFN-α2b, or rIFN-β1a; none received rIFN-β1b). RBV/rIFN was initiated at a median of 2 days (Q1, Q3: 1, 3 days) from intensive care unit admission. Crude 90-day mortality was higher in patients with RBV/rIFN compared to no RBV/rIFN (106/144 [73.6%] vs 126/205 [61.5%]; P = .02]. After adjusting for baseline and time-varying confounders using a marginal structural model, RBV/rIFN was not associated with changes in 90-day mortality (adjusted odds ratio, 1.03 [95% confidence interval {CI}, .73–1.44]; P = .87) or with more rapid MERS-CoV RNA clearance (adjusted hazard ratio, 0.65 [95% CI, .30–1.44]; P = .29). Conclusions: In this observational study, RBV/rIFN (RBV and/or rIFN-α2a, rIFN-α2b, or rIFN-β1a) therapy was commonly used in critically ill MERS patients but was not associated with reduction in 90-day mortality or in faster MERS-CoV RNA clearance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciz544

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 248

Metadata

Authors
Arabi, Y. M., Shalhoub, S., Mandourah, Y., Al-Hameed, F., Al-Omari, A., Al Qasim, E., Jose, J., Alraddadi, B., Almotairi, A., Al Khatib, K., Abdulmomen, A., Qushmaq, I., Sindi, A. A., Mady, A., Solaiman, O., Al-Raddadi, R., Maghrabi, K., Ragab, A., Al Mekhlafi, G. A., Balkhy, H. H., Al Harthy, A., Kharaba, A., Gramish, J. A., Al-Aithan, A. M., Al-Dawood, A., Merson, L., Hayden, F. G., & Fowler, R.
Venue
Clinical Infectious Diseases
Published
2019-06-25
Volume
70
Issue
9
Pages
1837-1844
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2955112665
Cited by
248
References
2
FWCI
38.27
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study. https://app.cochat.ai/papers/10.1093/cid/ciz544
The paper
Arabi, Y. M., Shalhoub, S., Mandourah, Y., Al-Hameed, F., Al-Omari, A., Al Qasim, E., Jose, J., Alraddadi, B., Almotairi, A., Al Khatib, K., Abdulmomen, A., Qushmaq, I., Sindi, A. A., Mady, A., Solaiman, O., Al-Raddadi, R., Maghrabi, K., Ragab, A., Al Mekhlafi, G. A., . . . Fowler, R. (2020). Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciz544

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.